ASX Share rice
Thu 13 May 2021 - 12:37:pm (Sydney)

ATX Share Price

AMPLIA THERAPEUTICS LIMITEDATXPharmaceuticals, Biotechnology & Life Sciences

ATX Company Information

Name:

Amplia Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

90 Collins Street Melbourne VIC Australia 3000

Phone:

61 2 8003 3650

CEO, MD & Director:

Dr. John Lambert B.Sc., BSc (Hons), MRACI, C.Chem., Ph.D.

Chief Financial Officer:

Mr. Jeff Carter

Company Sec.:

Mr. Andrew John Cooke LLB, FAICS, MAICD, FGIA, FCIS

Chief Scientific Officer:

Dr. Mark Devlin B.Sc., Ph.D.

Founding Scientist:

Dr. Frank Gelder

Trials Consultant:

Dr. James A. Taylor

Trials Consultant:

Dr. Michael H. Silverman B.Sc., M.B.A., M.D., F.A.C.P., FACR

Clinical Consultant:

Dr. Benjamin M. Segal

Toxicology Consultant:

Dr. Frederick E. Reno

Company Overview:

Amplia Therapeutics Limited, a pharmaceutical company, focuses on advancing a pipeline of focal adhesion kinase (FAK) inhibitors for cancer and fibrosis in Australia. The company's clinical development pipeline comprises two lead molecules, AMP945 and AMP886 that inhibits (FAK). It has a collaboration agreement with the Garvan Institute of Media Research in Sydney. The company was formerly known as Innate Immunotherapeutics Limited and changed its name to Amplia Therapeutics Limited in September 2018. Amplia Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

ATX Share Price Information

Shares Issued:

107.97M

Market Capitalisation:

$26.45M

Revenue (TTM):

$894.16K

Revenue Per Share (TTM):

$0.01

Earnings per Share:

$-0.047

Profit Margin:

-2.0639

Operating Margin (TTM):

$-2.13

Return On Assets (TTM):

$-0.11

Return On Equity (TTM):

$-0.18

Quarterly Revenue Growth (YOY):

168.434

Gross Profit(TTM):

$-88,991

Diluted Earnings Per Share (TTM):

$-0.028

ATX CashFlow Statement

CashFlow Date:

2020-03-31

Change To Liabilities:

$-16,239

Net Income:

$-2,219,474

Total Cash From Operating Activities:

$-2,087,977

Depreciation:

$801

Change To Account Receivables:

$-58,646

Sale Purchase Of Stock:

$2.15M

Capital Expenditures:

$0

ATX Income Statement

Income Date:

2020-03-31

Income Before Tax:

$-2,219,470

Net Income:

$-2,219,470

Operating Income:

$-2,223,190

Total Revenue:

$34.23K

ATX Balance Sheet

Balance Sheet Date:

2020-03-31

Intangible Assets:

$7.94M

Total Liabilities:

$510.62K

Total Stockholder Equity:

$8.61M

Other Current Liabilities:

$10.61K

Total Assets:

$9.12M

Common Stock:

$132.90M

Other Current Assets:

$10.89K

Retained Earnings:

$-122,926,082

Cash:

$1.11M

Total Current Liabilities:

$510.62K

Property - Plant & Equipment:

$797

Net Tangible Assets:

$667.83K

Total Current Assets:

$1.18M

Net Receivables:

$34.23K

Short-Term Investments:

$7.94M

Accounts Payable:

$474.07K

Short-Term Investments:

$7.94

Non Current Liabilities Total:

$0

ATX Share Price History

ATX News

24 Feb, 2021
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
26 Nov, 2020
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
30 May, 2020
Just because a business does not make any money, does not mean that the stock will go down. For example, although...